Does Caffeine Facilitate Human Reward Learning Behaviors?
Launched by YU-SHIUAN LIN · Apr 12, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring how caffeine affects our ability to learn from rewards. Researchers want to see if taking caffeine, either in a single dose or daily, can improve how we respond to rewards and learn new habits. Caffeine is a common substance that can change how our brain works by boosting signals related to pleasure and reward.
To participate in this study, individuals must be between 18 and 40 years old, in good health, and non-smokers. People who regularly consume very low or very high amounts of caffeine, pregnant or breastfeeding women, and those with certain health conditions or medications are not eligible. Participants can expect to take caffeine and then engage in tasks that measure their learning from rewards. This study is currently looking for volunteers, so if you're interested and meet the criteria, you could play a part in helping us understand more about how caffeine influences our learning processes.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age ≥ 18 and ≤ 40
- • Clinically healthy
- • Non-smokers
- Exclusion Criteria:
- • Habitual caffeine intake \< 100 mg or \> 450 mg
- • Pregnant or lactating women
- • Women using hormonal contraceptives
- • BMI \< 18.5 or \> 29.9
- • Sleep disturbance or extreme chronotypes
- • Nicotine or recreational drug users
- • Depression, anxiety, psychosis, or neurologic disorders
- • Severe heart or cardiovascular diseases
- • Diabetes or metabolic diseases
- • Under chronic medications
- • Incapable to operate the tasks or comprehend the study information in German or English
- • Users of the Bopomo alphates utilized as stimuli in the reward learning tasks
- • Current enrolment in other clinical trials
About Yu Shiuan Lin
Yu-Shiuan Lin is a dedicated clinical trial sponsor focused on advancing medical research and innovation. With a commitment to enhancing patient outcomes, Yu-Shiuan Lin oversees and manages clinical trials that explore novel therapeutic approaches across various therapeutic areas. Leveraging a robust network of clinical sites and a team of experienced professionals, the organization emphasizes rigorous study design, compliance with regulatory standards, and the ethical conduct of research. By fostering collaboration among stakeholders and prioritizing patient safety, Yu-Shiuan Lin aims to contribute significantly to the development of effective treatments and improve healthcare delivery.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Basel, Basel City, Switzerland
Patients applied
Trial Officials
Yu-Shiuan Lin, PhD
Principal Investigator
Centre for Chronobiology, University Psychiatric Clinics Basel
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials